Source library
Every study and official source we use, in one place. Filter by study type and what was studied.
Showing 80 of 80 sources
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
Jastreboff AM, Kaplan LM, Davies MJ, et al. N Engl J Med. 2026.
Used in: Retatrutide, What are peptides?, How to read a study, GLP-1, GIP and glucagon explained, Rules in Norway, Corrections
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Bajaj HS, Welch M, Shah P, et al. Lancet. 2026.
Used in: Retatrutide
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Mendias CL, Awan TM. Sports Med. 2026.
Used in: TB-500, Thymosin beta-4, What are peptides?
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026.
Used in: TB-500, Thymosin beta-4, GHK-Cu
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, et al. J Am Acad Orthop Surg Glob Res Rev. 2026.
Used in: TB-500
Thymosin beta-4, TMSB4X, human (P62328).
UniProt. 2026.
Used in: Thymosin beta-4
GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.
Mateescu DM, et al. Pharmaceutics. 2026.
Used in: GHK-Cu
CosIng: Copper Tripeptide-1 (cosmetic ingredient).
European Commission. 2026.
Used in: GHK-Cu, Rules in Norway
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo (NCT07437560).
ClinicalTrials.gov. 2026.
Used in: Melanotan II
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745).
ClinicalTrials.gov. 2026.
Used in: MOTS-c
Wegovy (semaglutide): EPAR. Authorised in the EU on 06.01.2022. Prescription only.
European Medicines Agency (EMA). 2026.
Used in: Semaglutide, What are peptides?, GLP-1, GIP and glucagon explained, Rules in Norway, Anti-doping
Mounjaro (tirzepatide): EPAR. Authorised in the EU on 15.09.2022. Prescription only.
European Medicines Agency (EMA). 2026.
Used in: Tirzepatide, What are peptides?, GLP-1, GIP and glucagon explained, Rules in Norway, Anti-doping
BPC 157 (CID 9941957).
PubChem, National Library of Medicine. 2026.
Used in: BPC-157
TB-500 (CID 62707662).
PubChem, National Library of Medicine. 2026.
Used in: TB-500, Thymosin beta-4
MOTS-c (CID 146675088).
PubChem, National Library of Medicine. 2026.
Used in: MOTS-c
Semax (CID 9811102).
PubChem, National Library of Medicine. 2026.
Used in: Semax
Lys-Pro-Val (KPV) (CID 125672).
PubChem, National Library of Medicine. 2026.
Used in: KPV
Melanotan II (CID 92432).
PubChem, National Library of Medicine. 2026.
Used in: Melanotan II
Ipamorelin (CID 9831659).
PubChem, National Library of Medicine. 2026.
Used in: CJC-1295 and ipamorelin
Copper tripeptide-1 (GHK-Cu) (CID 71587328).
PubChem, National Library of Medicine. 2026.
Used in: GHK-Cu
Import av legemidler til personlig bruk ved forsendelse.
Direktoratet for medisinske produkter (DMP). 2026.
Used in: Rules in Norway
Legemidler på reise inn til Norge.
Direktoratet for medisinske produkter (DMP). 2026.
Used in: Rules in Norway
Er produktet et legemiddel?
Direktoratet for medisinske produkter (DMP). 2026.
Used in: Rules in Norway
The 2026 Prohibited List. International Standard.
World Anti-Doping Agency (WADA). 2026.
Used in: Retatrutide, TB-500, Thymosin beta-4, Semaglutide, Tirzepatide, GHK-Cu, Melanotan II, MOTS-c, Semax, KPV, CJC-1295 and ipamorelin, Anti-doping
Seks peptider på dopinglisten av hensyn til folkehelsen.
Direktoratet for medisinske produkter (DMP). 2026.
Used in: Retatrutide, TB-500, Thymosin beta-4, GHK-Cu, Melanotan II, MOTS-c, Semax, KPV, CJC-1295 and ipamorelin, Rules in Norway
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Vasireddi N, Hahamyan H, Salata MJ, et al. HSS J. 2025.
Used in: BPC-157, How to read a study
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
McGuire FP, Martinez R, Lenz A, et al. Curr Rev Musculoskelet Med. 2025.
Used in: BPC-157
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Lee E, Burgess K. Altern Ther Health Med. 2025.
Used in: BPC-157
MOTS-C levels in individuals with and without obesity and its association with inflammation, insulin resistance and endothelial dysfunction.
Ozkaya DY, Haymana C, et al. Arch Endocrinol Metab. 2025.
Used in: MOTS-c
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. N Engl J Med. 2025.
Used in: Tirzepatide
Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review.
Wen J, et al. Nutr Metab Cardiovasc Dis. 2025.
Used in: GLP-1, GIP and glucagon explained
Netthandel: registreringsordning for nettapotek og andre utsalgssteder.
Direktoratet for medisinske produkter (DMP). 2025.
Used in: Rules in Norway
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Sanyal AJ, Kaplan LM, Frias JP, et al. Nat Med. 2024.
Used in: Retatrutide
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Lee E, Walker C, Ayadi B. Altern Ther Health Med. 2024.
Used in: BPC-157
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ, Sattar N, Horn DB, et al. JAMA. 2024.
Used in: Tirzepatide
Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, et al. N Engl J Med. 2023.
Used in: Retatrutide
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, et al. Lancet. 2023.
Used in: Retatrutide
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (NCT05984134).
ClinicalTrials.gov. 2023.
Used in: TB-500, Thymosin beta-4, Corrections
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.
Zheng Y, Wei Z, Wang T. Front Endocrinol (Lausanne). 2023.
Used in: MOTS-c
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. N Engl J Med. 2023.
Used in: Semaglutide, GLP-1, GIP and glucagon explained
Doping.
Direktoratet for medisinske produkter (DMP). 2023.
Used in: Anti-doping
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial.
Sosne G, Kleinman HK, Springs C, et al. Int J Mol Sci. 2022.
Used in: Thymosin beta-4
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022.
Used in: Tirzepatide, GLP-1, GIP and glucagon explained
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
Lee E, Padgett B. Altern Ther Health Med. 2021.
Used in: BPC-157
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
Reynolds JC, Lai RW, Woodhead JST, et al. Nat Commun. 2021.
Used in: MOTS-c
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021.
Used in: Semaglutide
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021.
Used in: Tirzepatide
Trends in peptide drug discovery.
Muttenthaler M, King GF, Adams DJ, Alewood PF. Nat Rev Drug Discov. 2021.
Used in: What are peptides?, How we work
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Kingsberg SA, Clayton AH, Portman D, et al. Obstet Gynecol. 2019.
Used in: Melanotan II
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
Pickart L, Margolina A. Int J Mol Sci. 2018.
Used in: GHK-Cu
A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (NCT03998514).
ClinicalTrials.gov. 2018.
Used in: MOTS-c
The efficacy of semax in the treatment of patients at different stages of ischemic stroke. In Russian.
Gusev EI, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2018.
Used in: Semax
Effects of Semax on the Default Mode Network of the Brain.
Lebedeva IS, Panikratova YR, Sokolov OY, et al. Bull Exp Biol Med. 2018.
Used in: Semax, How to read a study
Ozempic (semaglutide): EPAR. Authorised in the EU on 08.02.2018.
European Medicines Agency (EMA). 2018.
Used in: Semaglutide, GLP-1, GIP and glucagon explained
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Drucker DJ. Cell Metab. 2018.
Used in: What are peptides?, GLP-1, GIP and glucagon explained
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.
Xiao B, et al. Mol Ther. 2017.
Used in: KPV
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C, Harashima SI, Tsoukas GM, et al. Lancet Diabetes Endocrinol. 2017.
Used in: Semaglutide
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016.
Used in: Semaglutide
Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Sosne G, Dunn SP, Kim C. Cornea. 2015.
Used in: TB-500, Thymosin beta-4
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
Sosne G, Ousler GW. Clin Ophthalmol. 2015.
Used in: Thymosin beta-4
Afamelanotide for Erythropoietic Protoporphyria.
Langendonk JG, Balwani M, Anderson KE, et al. N Engl J Med. 2015.
Used in: Melanotan II
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015.
Used in: MOTS-c, What are peptides?
Scenesse (afamelanotide): EPAR. Authorised in the EU on 22.12.2014.
European Medicines Agency (EMA). 2014.
Used in: Melanotan II
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
Beck DE, et al. Int J Colorectal Dis. 2014.
Used in: CJC-1295 and ipamorelin
Lost in translation: animal models and clinical trials in cancer treatment.
Mak IW, Evaniew N, Ghert M. Am J Transl Res. 2014.
Used in: How to read a study, How we work
The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients.
Treadwell T, Kleinman HK, Crockford D, et al. Ann N Y Acad Sci. 2012.
Used in: Thymosin beta-4
The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study.
Stavchansky VV, et al. J Mol Neurosci. 2011.
Used in: Semax
The effect of thymosin treatment of venous ulcers.
Guarnera G, DeRosa A, Camerini R. Ann N Y Acad Sci. 2010.
Used in: TB-500, Thymosin beta-4
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. Gastroenterology. 2008.
Used in: KPV
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
Kannengiesser K, Maaser C, Heidemann J, et al. Inflamm Bowel Dis. 2008.
Used in: KPV, What are peptides?
Biology of incretins: GLP-1 and GIP.
Baggio LL, Drucker DJ. Gastroenterology. 2007.
Used in: GLP-1, GIP and glucagon explained
Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.
Dolotov OV, et al. J Neurochem. 2006.
Used in: Semax
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL, et al. J Clin Endocrinol Metab. 2006.
Used in: CJC-1295 and ipamorelin, How to read a study
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006.
Used in: CJC-1295 and ipamorelin
alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.
Elliott RJ, et al. J Invest Dermatol. 2004.
Used in: KPV
Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.
Wessells H, Gralnek D, Dorr R, et al. Urology. 2000.
Used in: Melanotan II
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.
Wessells H, Fuciarelli K, Hansen J, et al. J Urol. 1998.
Used in: Melanotan II
Ipamorelin, the first selective growth hormone secretagogue.
Raun K, Hansen BS, Johansen NL, et al. Eur J Endocrinol. 1998.
Used in: CJC-1295 and ipamorelin
Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). In Russian.
Gusev EI, Skvortsova VI, Miasoedov NF, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 1997.
Used in: Semax
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Dorr RT, Lines R, Levine N, et al. Life Sci. 1996.
Used in: Melanotan II
No sources match the filter.